Clinical Trial Update: Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE) [Phase 3]

View source ↗

Summary

Phase 3 trial of denosumab as adjuvant therapy in women with high-risk early breast cancer has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Denosumab (denosumab)

Snippet

Sponsor: Amgen | Conditions: Breast Cancer | Phase 3 | Status: TERMINATED | Results posted: 2018-10-03